Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities

被引:13
作者
Liu, Pan [1 ]
Jin, Yanxia [1 ]
Sattar, Haseeb [2 ]
Liu, Hailing [3 ]
Xie, Weiling [1 ]
Zhou, Fuling [1 ,4 ]
机构
[1] Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Hosp, Dept Clin Pharm,Wuhan Union Hosp, Wuhan, Hubei, Peoples R China
[3] Xi An Jiao Tong Univ, Dept Clin Hematol, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China
[4] Hubei Key Lab Tumor Biol Behav, Wuhan, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
immunotherapy; multiple myeloma; natural killer cell; HLA CLASS-I; NK CELLS; MEDIATED LYSIS; MONOCLONAL-ANTIBODIES; CANCER-IMMUNOTHERAPY; BISPECIFIC ANTIBODY; THERAPEUTIC TARGET; ADOPTIVE TRANSFER; T-CELLS; ACTIVATION;
D O I
10.1002/JLB.2RU0517-176RR
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Multiple myeloma (MM) is a complex aggressive mature B-cell malignancy. Although with the wide application of chemotherapy drugs, it remains incurable and the vast majority of patients relapse. Natural killer (NK) cells, also known as CD56(+)CD3(-) large granular lymphocytes, are cytotoxic innate immune cells against MM without prior sensitization steps. NK cell-based immunotherapy is extensively promising in a wide range of clinical settings. It is worthy of note that some novel drugs such as monoclonal antibodies (mAbs), proteasome inhibitors (PIs), and immunomodulators (IMiDs) directly or indirectly activate NK cells to enhance their antitumor activity, and the combined regimens significantly improve the prognosis of MM patients. In this review, we summarize recent findings that support a role for NK cells in the pathogenesis of MM and outline innovative approaches in the implementation of NK cell-based immunotherapy against MM. Review on NK cell dysfunction in patients with multiple myeloma.
引用
收藏
页码:821 / 828
页数:8
相关论文
共 95 条
[41]   KIR genotype distribution among patients with multiplemyeloma: Higher prevalence of KIR 2DS4 and KIR 2DS5 genes [J].
Hoteit, R. ;
Bazarbachi, A. ;
Antar, A. ;
Salem, Z. ;
Shammaa, D. ;
Mahfouz, R. .
META GENE, 2014, 2 :730-736
[42]   CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma [J].
Hsi, Eric D. ;
Steinle, Roxanne ;
Balasa, Balaji ;
Szmania, Susann ;
Draksharapu, Aparna ;
Shum, Benny P. ;
Huseni, Mahrukh ;
Powers, David ;
Nanisetti, Amulya ;
Zhang, Yin ;
Rice, Audie G. ;
van Abbema, Anne ;
Wong, Melanie ;
Liu, Gao ;
Zhan, Fenghuang ;
Dillon, Myles ;
Chen, Shihao ;
Rhodes, Susan ;
Fuh, Franklin ;
Tsurushita, Naoya ;
Kumar, Shankar ;
Vexler, Vladimir ;
Shaughnessy, John D., Jr. ;
Barlogie, Bart ;
van Rhee, Frits ;
Hussein, Mohamad ;
Afar, Daniel E. H. ;
Williams, Marna B. .
CLINICAL CANCER RESEARCH, 2008, 14 (09) :2775-2784
[43]   N-Acetyl-D-glucosamine-coated polyamidoamine dendrimer promotes tumor-specific B cell responses via natural killer cell activation [J].
Hulikova, Katarina ;
Svoboda, Jan ;
Benson, Veronika ;
Grobarova, Valeria ;
Fiserova, Anna .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2011, 11 (08) :955-961
[44]   A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer [J].
Iliopoulou, Eleni G. ;
Kountourakis, Panteleimon ;
Karamouzis, Michalis V. ;
Doufexis, Dimitrios ;
Ardavanis, Alexandros ;
Baxevanis, Constantin N. ;
Rigatos, Gerasimos ;
Papamichail, Michael ;
Perez, Sonia A. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (12) :1781-1789
[45]   Transfection of chimeric anti-CD 138 gene enhances natural killer cell activation and killing of multiple myeloma cells [J].
Jiang, Hua ;
Zhang, Wenhao ;
Shang, Peipei ;
Zhang, Hui ;
Fu, Weijun ;
Ye, Fei ;
Zeng, Tianmei ;
Huang, Hejing ;
Zhang, Xueguang ;
Sun, Wanping ;
Sze, Daniel Man-Yuen ;
Yi, Qing ;
Hou, Jian .
MOLECULAR ONCOLOGY, 2014, 8 (02) :297-310
[46]   Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells [J].
Jungkunz-Stier, Isabel ;
Zekl, Michael ;
Stuehmer, Thorsten ;
Einsele, Hermann ;
Seggewiss-Bernhardt, Ruth .
LEUKEMIA & LYMPHOMA, 2014, 55 (01) :168-176
[47]   Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells [J].
Kim, Jong R. ;
Mathew, Stephen O. ;
Mathew, Porunelloor A. .
IMMUNOBIOLOGY, 2016, 221 (01) :31-39
[48]   Natural Killer Cells for immunotherapy-Advantages of the NK-92 Cell Line over Blood NK Cells [J].
Klingemann, Hans ;
Boissel, Laurent ;
Toneguzzo, Frances .
FRONTIERS IN IMMUNOLOGY, 2016, 7
[49]  
Krzewski K, FRONT IMMUNOL, V3, P335
[50]   Pomalidomide [J].
Lacy, Martha Q. ;
McCurdy, Arleigh R. .
BLOOD, 2013, 122 (14) :2305-2309